Recruiting studies: Anthracycline Related Cardiotoxicity In Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Phase 1/Phase 2 · 1 location(s) · Texas Tech University Health Sciences Center · NCT03934905 Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Phase 4 · 4 location(s) · Silesian Centre for Heart Diseases · NCT05465031 Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Phase 2 · 1 location(s) · University Hospital, Akershus · NCT05732051 ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Phase N/A · 1 location(s) · University Hospital, Caen · NCT07191730 Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
NA · 1 location(s) · Erasmus Medical Center · NCT06622954 Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
NA · 3 location(s) · Virginia Commonwealth University · NCT07426913 Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
NA · 2 location(s) · University of Aberdeen · NCT07070765

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.